April 3 (Reuters) - Biotechnology firm Alterome

Therapeutics said on Wednesday it has raised $132 million in a

series B financing round, which was led by Goldman Sachs

Alternatives.

The series B financing, which brings its total funding to

nearly $232 million to date, also saw participation by Canaan

Partners, Driehaus Capital Management, Invus, Digitalis

Ventures, Blue Owl Capital, and existing investors.

The company said in a statement that the proceeds will be

used to "support the advancement of multiple wholly-owned

pipeline programs," including two precision oncology programs

into clinical development within 12 months.

The cancer therapy-focused firm's funding round comes after

a gap of more than two years. It originally raised $64 million

in a series A round in January 2022.

Startup funding in the United States has declined in the

past year as the venture capital market continues to grapple

with valuation resets and an uncertain macro environment.

However, an artificial intelligence boom and rising bets

of interest rate cuts have encouraged investors to loosen their

pockets this year.

The company, founded in 2022, uses its in-house Kraken

platform - a structure-guided machine learning approach - to

develop therapies for cancer patients.

Alterome did not immediately reply to Reuters' request on

its post-funding market valuation.

(Reporting by Jaiveer Singh Shekhawat in Bengaluru; Editing by

Varun H K)